Gold prices buoyed by tariff fears; US duties on 1-kilo bars spur supply concerns
WILMINGTON, Del. - Biopharmaceutical company Incyte (NASDAQ:INCY), currently valued at $15.15 billion and showing strong financial health according to InvestingPro metrics, announced Tuesday that Executive Vice President and Chief Financial Officer Christiana Stamoulis will leave the company effective September 16, 2025, to pursue another opportunity.
Stamoulis, who joined Incyte in 2019, will remain with the company until her departure date to facilitate a smooth transition. The company has already begun the search for her successor.
"Since joining Incyte in 2019, Christiana has been an invaluable part of the leadership team," said Bill Meury, President and Chief Executive Officer of Incyte.
Despite the leadership change, Incyte reaffirmed its financial guidance for 2025 as disclosed during its second-quarter earnings announcement on July 29. The company stated that its financial position and strategic direction remain unchanged.
Incyte, headquartered in Wilmington, Delaware, focuses on developing and commercializing therapeutics for patients with unmet medical needs, with a portfolio concentrated in oncology and inflammation and autoimmunity treatments.
The announcement comes as part of a press release statement that included standard forward-looking statements and disclaimers regarding the company’s operations and financial outlook.
In other recent news, Incyte reported a strong second-quarter performance for 2025, with earnings surpassing consensus expectations. Jakafi sales were particularly notable, reaching $764 million, exceeding the anticipated $743 million. Niktimvo also showed impressive growth, generating $36 million in revenue, marking a 166% increase quarter-over-quarter. Following these results, TD Cowen raised its price target for Incyte to $89, maintaining a Buy rating due to the robust performance across all product lines. Truist Securities also increased its price target to $79, noting the strong sales figures for Jakafi. Barclays initiated coverage on Incyte with an Overweight rating, highlighting the company’s potential for revenue growth in the coming years. RBC Capital raised its price target to $72, driven by demand for Incyte’s products, including Jakafi and Niktimvo. BMO Capital adjusted its price target to $60, expressing cautious optimism about the company’s future under new leadership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.